R&D expense · 2011–2025
Neurocrine Biosciences R&D expense
$1.0B+38.9% · FY2025
Neurocrine Biosciences (NBIX) reported $1.0B in R&D expense for fiscal 2025, +38.9% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $1.0B | +38.9% | Open → |
| FY20242024-12-31 | $731M | +29.4% | Open → |
| FY20232023-12-31 | $565M | +21.8% | Open → |
| FY20222022-12-31 | $464M | +41.4% | Open → |
| FY20212021-12-31 | $328M | +19.3% | Open → |
| FY20202020-12-31 | $275M | +71.3% | Open → |
| FY20182018-12-31 | $161M | +31.8% | Open → |
| FY20172017-12-31 | $122M | +29.2% | Open → |
| FY20162016-12-31 | $94.3M | +15.7% | Open → |
| FY20152015-12-31 | $81.5M | +75.5% | Open → |
| FY20142014-12-31 | $46.4M | +18.3% | Open → |
| FY20132013-12-31 | $39.2M | +5.6% | Open → |
| FY20122012-12-31 | $37.2M | +20.1% | Open → |
| FY20112011-12-31 | $31.0M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +28.3%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neurocrine Biosciences R&D expense |url=https://companiesranked.com/en/company/neurocrine-biosciences/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neurocrine Biosciences R&D expense. CompaniesRanked. https://companiesranked.com/en/company/neurocrine-biosciences/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-neurocrine-biosciences-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Neurocrine Biosciences R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neurocrine-biosciences/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000914475-26-000007 · February 11, 2026
{{cite web |title=Neurocrine Biosciences R&D expense — 10-K (0000914475-26-000007) |url=https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.